Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isosorbide Mononitrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | BCHE | P06276 | 6/20 | 0.58 |
| ▸ | GSR | P00390 | 7/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isosorbide Mononitrate SCHEMBL8893635 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL12238510 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL8894719 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL3056251 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL5482432 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL23906861 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL12787633 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL26782 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL22067709 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL8893344 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3238720-A1 | ANTI-METHANOGENIC COMPOSITIONS AND USES THEREOF | DSM IP Assets B.V. (NL) | 2017-11-01 | — | — | EP | claimed |
| WO-2010005687-A1 | COMPOSITIONS COMPRISING NITRIC OXIDE OR NITRIC OXIDE DONORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR TRAUMA | UNIVERSITY OF ALABAMA HUNTSVILLE (US) | 2010-01-14 | — | — | WO | claimed |
| WO-2009152479-A1 | COMPOSITIONS COMPRISING NITRIC OXIDE OR NITRIC OXIDE DONORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OF TRAUMA | UNIVERSITY OF ALABAMA HUNTSVILLE (US) | 2009-12-17 | — | — | WO | claimed |
| US-20020006435-A1 | Transdermal anesthetic and vasodilator composition and methods for topical administration | SAMUELS PAUL J (US) | 2002-01-17 | — | — | US | claimed |
| WO-2001054679-A2 | TRANSDERMAL COMPOSITION CONTAINING AN ANESTHETIC AND A VASODILATOR AGENT | CHILDREN'S HOSPITAL RESEARCH FOUNDATION (US) | 2001-08-02 | — | — | WO | claimed |
| WO-1989005302-A1 | AMINOPROPANOL DERIVATIVES OF 1,4:3,6-DIANHYDRO-HEXITOL NITRATES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | HEINRICH MACK NACHF. (DE) | 1989-06-15 | — | — | WO | claimed |
| EP-0319030-A1 | Aminopropanol derivatives of 1,4:3,6-dianhydro-hexitol nitrates, processes for their preparation and their use as medicaments | Heinrich Mack Nachf. (DE) | 1989-06-07 | — | — | EP | claimed |
| EP-0230557-A2 | 2,6-Dioxabicyclo[3.3.0]octane derivatives, their preparation and use as medicament | Heinrich Mack Nachf. (DE) | 1987-08-05 | — | — | EP | claimed |
| CN-117229211-B | NO donor type roflumilast derivative, preparation method, composition and application | 武汉科技大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-4175943-B1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS BEIJING CO LTD (CN) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024182375-A1 | COMPOSITIONS COMPRISING NITRIC OXIDE-RELEASING COMPOUNDS FOR TREATING CHOROIDAL VASCULAR DISEASES AND METHODS OF THEIR USE | OPTICGON LLC (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240285572-A1 | COMPOSITIONS COMPRISING NITRIC OXIDE-RELEASING COMPOUNDS FOR TREATING CHOROIDAL VASCULAR DISEASES AND METHODS OF THEIR USE | OPTICGON LLC | 2024-08-29 | — | — | US | disclosed |
| US-11987556-B2 | Dual-functional compounds and methods of use | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2024-05-21 | — | — | US | disclosed |
| US-20230174482-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2023-06-08 | — | — | US | disclosed |
| US-4891373-A | ANGINA PECTORIS; HYPOTENSIVE | PFIZER INC. (US) | 1990-01-02 | — | — | US | disclosed |
| WO-1989005302-A1 | AMINOPROPANOL DERIVATIVES OF 1,4:3,6-DIANHYDRO-HEXITOL NITRATES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | HEINRICH MACK NACHF. (DE) | 1989-06-15 | — | — | WO | disclosed |
| WO-1989005302-A1 | AMINOPROPANOL DERIVATIVES OF 1,4:3,6-DIANHYDRO-HEXITOL NITRATES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | HEINRICH MACK NACHF. (DE) | 1989-06-15 | — | — | WO | disclosed |
| EP-0319030-A1 | Aminopropanol derivatives of 1,4:3,6-dianhydro-hexitol nitrates, processes for their preparation and their use as medicaments | Heinrich Mack Nachf. (DE) | 1989-06-07 | — | — | EP | disclosed |
| EP-0319030-A1 | Aminopropanol derivatives of 1,4:3,6-dianhydro-hexitol nitrates, processes for their preparation and their use as medicaments | Heinrich Mack Nachf. (DE) | 1989-06-07 | — | — | EP | disclosed |
| EP-0319030-A1 | Aminopropanol derivatives of 1,4:3,6-dianhydro-hexitol nitrates, processes for their preparation and their use as medicaments | Heinrich Mack Nachf. (DE) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174482-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | PDE1A, PDE3B, PDE1B | MAPT 4041/4885ALDH1A1 471/4885BCHE 113/4885 |
| US-11987556-B2 | Dual-functional compounds and methods of use | PDE1A, PDE3B, PDE1B | MAPT 4041/4885ALDH1A1 471/4885BCHE 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.